

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on a preliminary review of the Company's unaudited consolidated management accounts for the six months ended 30 June 2020, the profit attributable to equity holders of the Company for the six months ended 30 June 2020 is expected to record a drop ranging from 50% to 60% as compared with that of the same period of 2019.

The information contained in this announcement is only based on a preliminary review of the Company's unaudited consolidated management accounts for the six months ended 30 June 2020. Such management accounts have not been reviewed by the Company's auditor or the audit committee of the Company.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by SSY Group Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the Company’s unaudited consolidated management accounts for the six months ended 30 June 2020, the profit attributable to equity holders of the Company for the six months ended 30 June 2020 (the “**profit**”) is expected to record a drop ranging from 50% to 60% as compared with that of the same period of 2019. Such expected drop was mainly due to the outbreak of the novel coronavirus (“**COVID-19**”) pandemic which began in early 2020. Because of a significant reduction of human traffic in hospitals in China, which are major customers of the Group, sales of the Group’s products including intravenous infusion solutions have been affected. In addition, the Group’s sales are denominated in Renminbi (“**RMB**”), which depreciated by approximately 4.8% for the six months ended 30 June 2020 as compared with the same period of 2019 when translated into Hong Kong dollars (“**HK\$**”), which caused a drop in the profit of the Group which is represented in HK\$.

Notwithstanding the above, the Board believes that the Group still maintains a solid financial position and cash flow. During the first half year of 2020, the Group has been actively responding to the China government’s measures in fighting against COVID-19 pandemic. For example, the Group has increased its supply of Abidol Hydrochloride capsules, the antiviral drug, through “green channels” of drug procurements in various provinces and “shipping orders” from the State Council of China. On the other hand, the Group has taken effective measures to minimize the impact of COVID-19 pandemic on its business. For example, the Group has been using the “Internet +” model to meet customer needs without face-to-face, controlling its operating costs, as well as pushing forward enterprise innovations and high-quality developments. The Group will keep continuous attention on the change of situation and make timely responses.

The information contained in this announcement is only based on a preliminary review of the Company’s unaudited consolidated management accounts for the six months ended 30 June 2020 and the information currently available to the Board. It is not based on any figures or information that have been reviewed by the Company’s auditor, or reviewed by the audit committee of the Company. The Company is still in the process of finalising the consolidated interim results of the Group for the six months ended 30 June 2020. The finalised consolidated interim results and other details of the Group for the six months ended 30 June 2020 will be published by the Company within the timeframe as stipulated under the Listing Rules.

**Shareholders and potential investors are advised to read this announcement carefully and exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 7 August 2020

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*